Zanolimumab

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 06:32, 11 January 2012 (Updating {{drugbox}} (changes to verified fields - added verified revid - updated 'ChEMBL_Ref', 'ChEBI_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report errors...). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Zanolimumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetCD4
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
UNII
KEGG
Chemical and physical data
Molar mass147 kDa
 ☒NcheckY (what is this?)  (verify)

Zanolimumab (expected trade name HuMax-CD4[1]) is a human monoclonal antibody and an immunosuppressive drug. It is being developed for the treatment of rheumatoid arthritis, psoriasis, melanoma,[2] cutaneous and peripheral T-cell lymphoma.[3][4] The drug is currently undergoing Phase II trials[5] .

References

  1. ^ Genmab initiates Phase II Study with HuMax-CD4
  2. ^ http://www.tenxbiopharma.com/development.shtml
  3. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
  4. ^ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov
  5. ^ "Status of clinical trials for Zanolimumab". Retrieved 6 November 2011.


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Zanolimumab&oldid=470748878"